MarcelliD., StanhardD., ConteF., HeldP.J., LocatelliF., PortF.K.. ESRD patient mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the Unites States.Kidney Int1996; 50: 1013–8.
5.
LocatelliF., MarcelliD., ConteF.. 1983 to 1992: report on regular dialysis and transplantation in Lombardy.Am J Kidney Dis1995; 25: 196–205.
6.
MaisonneuveP., AgodoaL., GellertR.. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.Lancet1999; 354: 93–9.
7.
GanemD., VarmusH.E.. The molecular biology of the hepatitis B viruses.Annu Rev Biochem1987; 56: 651–93.
8.
FabriziF., MartinP.. Hepatitis B infection in dialysis patients.Am J Nephrol2000; 20: 1–11.
9.
TelesS.A., MartinsR.M.B., VanderborghtB., StuyverL., GasparA.M.C., YoshidaC.F.T.. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients.Artif Organs1999; 23: 1074–8.
10.
ZuckermanA.J., ZuckermanJ.N.. Molecular epidemiology of hepatitis B virus mutants.J Med Virol1999; 58: 193–5.
11.
RibotS., RothsteinM., GoldblatM., GrassoM.. Duration of hepatitis B surface antigenemia in hemodialysis patients.Arch Intern Med1979; 139: 178–80.
12.
HarnettJ.D., ParfreyP.S., KennedyM., ZeldisJ.B., SteinmanT.I., GuttmannR.D.. The long-term outcome of hepatitis B infection in hemodialysis patients.Am J Kidney Dis1988; 11: 210–3.
13.
DegottC., DegosF., JungersP.. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis.Liver1983; 3: 377–84.
14.
CouglinA.P., van DethA.G., DisneyA.P.S., HayJ., WargelA.G.. Liver disease and the e antigen in HBsAg carriers with chronic renal failure.Gut1980; 21: 118–22.
15.
GalbraithR., el SheikhN., PortmannB.. Immune response to HBsAg and the spectrum of liver lesions in HBsAg-positive patients with chronic renal disease.Br J Med1976; 1: 1495–7.
16.
ParfreyP.S., FargeD., ForbesR.D.C., DandavinoR., KennickS., GuttmannR.D.. Chronic hepatitis in end-stage renal disease: comparison of HBsAg-negative and HBsAg-positive patients.Kidney Int1985; 28: 959–67.
17.
ParfreyP.S., ForbesR.D.C., HutchinsonT.A.. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients.Transplantation1984; 37: 461–5.
18.
HarnettJ.D., ZeldisJ.B., ParfreyP.S.. Hepatitis B disease in dialysis and renal transplant patients. Further epidemiologic and serologic studies.Transplantation1987; 44: 369–76.
19.
FornaironS., PolS., LegendreC.. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection.Transplantation1996; 62: 297–9.
20.
MathurinP., MouquetC., PoynardT.. Impact of hepatitis B and C virus on kidney transplantation outcome.Hepatology1999; 29: 257–63.
21.
YasudaK., OkudaK., EndoN.. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal.Gastroenterology1995; 109: 1295–100.
22.
FabriziF., MartinP., DixitV.. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey.Nephron1998; 90: 428–33.
23.
FabriziF., LunghiG., AndrulliS.. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients.Nephrol Dial Transplant1997; 12: 1394–8.
24.
GuhY.H., LaiY.H., YangC.Y.. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients.Nephron1995; 69: 459–65.
25.
JosselsonJ., KyserB.A., WeirM.R., SadlerJ.H.. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality.Am J Kidney Dis1987; 9: 456–61.
26.
JhaR., KherV., NaikS., ElhenseR., GutpaA., SharmaR.K.. Hepatitis B associated liver disease in dialysis patients: role of vaccination.J Nephrol1993; 6: 98–103.
27.
AlterM.J., FaveroM.S., PetersenN.J., DotoI.L., LegerR.T., MaynardJ.E.. National surveillance of dialysis-associated hepatitis and other diseases, 1976–1980.Dial Transplant1983; 12: 860–5.
28.
AlterM.J., FaveroM.S., MillerJ.K., MoyerL.A., BlandL.A.. National surveillance of dialysis-associated diseases in the United States, 1987.Trans ASAIO1989; 35: 820–31.
29.
AlterM.J., FaveroM.S., MillerJ.K., MoyerL.A., BlandL.A.. National surveillance of dialysis-associated diseases in the United States, 1988.ASAIO J1990; 36: 107–18.
30.
AlterM.J., FaveroM.S., MillerJ.K., MoyerL.A., BlandL.A.. National surveillance of dialysis-associated diseases in the United States, 1989.ASAIO J1991; 37: 97–109.
31.
TokarsJ.I., AlterM.J., FaveroM.S., MoyerL.A., BlandL.A.. National surveillance of hemodialysis-associated diseases in the United States, 1990.ASAIO J1993; 39: 71–80.
32.
TokarsJ.I., AlterM.J., FaveroM.S., MoyerL.A., BlandL.A.. National surveillance of hemodialysis-associated diseases in the United States, 1991.ASAIO J1993; 39: 966–75.
33.
TokarsJ.I., AlterM.J., FaveroM.S., MoyerL.A., MillerE., BlandL.A.. National surveillance of dialysis-associated diseases in the United States, 1992.ASAIO J1994; 40: 1020–31.
34.
TokarsJ.I., AlterM.J., FaveroM.S., MoyerL.A., MillerE., BlandL.A.. National surveillance of dialysis associated diseases in the United States, 1993.ASAIO J1996; 42: 219–29.
35.
TokarsJ.L., AlterM.J., MillerE., MoyerL.A., FaveroM.S.. National surveillance of dialysis associated diseases in the United States- 1994.ASAIO J1997; 43: 109–19.
36.
TokarsJ.L., MillerE.R., AlterM.J., ArduinoM.J.. National surveillance of dialysis associated diseases in the United States, 1995.ASAIO J1998; 44: 98–107.
37.
Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in health-care settings.Morb Mortal Wkly Rep1988; 37: 377–82.
38.
LimidoA., ConteF., MalbertiF., SpottiD., MarcelliD., LocatelliF.. Misure di profilassi delle infezioni da virus B e C in Lombardia: Dati del Registro Lombardo Dialisi e Trapianto (RLDT).Giorn It Nefrol2000; 266A.
39.
Center for Disease Control and Prevention.Outbreaks of hepatitis B virus infection among chronic haemodialysis patients, California, Nebraska, and Texas, 1994.Morb Mortal Wkly Rep1996; 45: 285–9.
40.
TanakaS., YoshibaN., IinoS.. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutants.Kidney Int1995; 48: 1972–8.
41.
RollM., NorderH., MagniusL.O., GrillnerL., LingrenV.. Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing.J Hosp Infection1995; 30: 57–63.
FernandezE., BetrinM.A., GomezR., MontoliuJ.. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality.Nephrol Dial Transplant1996; 11: 1559–63.
44.
LombardiM., PizzarelliF., RighiM.. Hepatitis B vaccination in dialysis patients and nutritional status.Nephron1992; 61: 266–8.
45.
PozzilliP., ArduiniP., VisalliN.. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes.Diabetologia1987; 30: 817–9.
46.
StevensC.E., SzmunessW., GoodmanA.I., WeseleyS.A., FotinoM.. Hepatitis B vaccine: immune responses in hemodialysis patients.Lancet1980; 2: 1211–3.
47.
VagelliG., CalabreseG., MazzottaA., PratesiG., GonellaM.. More about response to hepatitis B vaccine in hemodialysis patients.Nephron1988; 49: 171 (letter).
48.
SteketeeR.W., ZiamikM.E., DavisJ.P.. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Visconsin.Am J Epidemiol1988; 127: 772–82.
49.
SennesaelJ.J., van der NiepenP., VerbeelenD.L.. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients.Kidney Int1991; 40: 121–8.
50.
NavarroJ.F., TeruelJ.L., MateosM.L., MarcenR., OrtunoJ.. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection.Am J Nephrol1996; 16: 95–7.
51.
KhanA.N., BernardiniJ., RaultR.M., PirainoB.. Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients.Perit Dial Int1996; 16: 370–3.
52.
JibaniM.M., HeptonstallJ., WalkerA.M., BloodworthL.O., HowardA.J.. Hepatitis B immunization in UK renal units. Failure to put policy into practice.Nephrol Dial Transplant1994; 9: 1765–8.
53.
FabriziF., Di FilippoS., MarcelliD.. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis.Nephron1996; 72: 536–43.
54.
BenhamouE., CouroucéA.M., JungersP.. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients.Clin Nephrol1984; 21: 143–7.
55.
BrugueraM., CremadesM., MayorA., Sanchez TapiasJ.M., RodesJ.. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients.Postgrad Med J1987; 63(2): 155–8.
56.
JilgW., SchmidtM., WeinelB.. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients.J Hepatol1986; 3: 190–5.
57.
WalzG., KunzendorfU., HallerH.. Factors influencing the response to hepatitis B vaccination of hemodialysis patients.Nephron1989; 51: 474–7.
58.
DenticoP., BuongiornoR., VolpeA.. Long term immunogenicity and protective efficacy of recombinant DNA yeast-derived vaccine in hemodialysis patients.J Nephrol1993; 6: 95–7.
59.
de GraeffP.A., DankertJ., De ZeuwD., GipsC.H., van derHem. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up.Nephron1985; 40: 155–60.
60.
GuanR., ChoongL.. Immunogenicity of a recombinant DNA hepatitis B vaccine in patients with chronic renal failure.Epidemiol News Bull1989; 15(8): 45–6.
61.
MitwalliA.. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.Nephron1996; 73: 417–20.
62.
AlbertoniF., BattilomoA., Di NardoV.. and The Latium Hepatitis Prevention Group. Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: experience in an Italian region.Nephron1991; 58: 180–3.
63.
KohlerH., ArnoldW., RenschinG., DormeyerH.H., Meyer zum BuschenfeldeK.H.. Active hepatitis B vaccination of dialysis patients and medical staff.Kidney Int1984; 25: 124–8.
64.
CarrenoV., MoraI., EscuinF.. Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule ?Clin Nephrol1985; 24: 215–20.
65.
BommerJ., RitzE., AndrassyK.. Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients.Proc EDTA1983; 20: 161–8.
66.
DocciD., CipolloniP.A., MengozziS., BaldratiL., CapponciniC., FelettiC.. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up.Nephron1992; 61: 352–4.
67.
DrachmanR., IsachsonM., RudenskiB., DrukkerA.. Vaccination against hepatitis B in children and adolescent patients on dialysis.Nephrol Dial Transplant1989; 4: 372–4.
68.
ButiM., ViladomiuL., JardiR.. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients.Am J Nephrol1992; 12: 144–7.
69.
van GeelenJ.A., SchalmS.W., de VissenE.M., HeijtinkR.A.. Immune response to hepatitis B vaccine in hemodialysis patients.Nephron1987; 45: 216–8.
70.
WaiteN.M., ThomsonL.G., GoldsteinM.B.. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine.J Am Soc Nephrol1995; 5: 1930–4.
71.
MettangT., SchenkU., ThomsS.. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure.Nephron1996; 72: 192–6.
72.
OnoK., KashiwagiS.. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients.Nephron1991; 1: 47–51.
73.
FabriziF., AndrulliS., BacchiniG., CortiM., LocatelliF.. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective study with cost-effectiveness evaluation.Nephrol Dial Transplant1997; 12: 1394–8.
74.
PouxJ.M., RangerS., LagardeC.. Efficacy of intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients.Nephrol Dial Transplant1994; 7: 1213–4 (letter).
75.
ChangP.C., Schrander-van der MeerA.M., van DorpW.T., van LeerE.. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients.Nephrol Dial Transplant1996; 11: 191–3.
76.
VlassopoulosD., ArvanitisD., LilisD., KatopodisK., LouizouK., HadjinconstantinouV.. Low repeated doses of intradermal hepatitis B vaccine produce protective levels of antibodies in hemodialysis patients, non-responding to usual and double multiple doses.J Nephrol1994; 7: 340–1.
77.
MarangiA.L., GiordanoR., MontanaroA.. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination.Am J Kidney Dis1994; 23: 537–42.
78.
RawerP., WillemsW.R., BreidenbachT., GuttmannW., PabstW., SchutterleG.. Seroconversion rate, hepatitis B vaccination, hemodialysis, and zinc supplementation.Kidney Int1987; 32(Suppl 22): S149–52.
79.
BrodersenH.P., HoltkampW., LarbigD.. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study.Nephrol Dial Transplant1995; 10: 1780 (letter).
80.
GrobP.J., Joller-JemmelkaH.I., BinswangerU., ZarubaK., DescoeundresC., FernexM.. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder population.Eur J Clin Microbiol1984; 3: 195–8.
81.
QuirogaJ.A., CastilloI., PorresJ.C.. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients.Hepatology1990; 12: 661–3.
82.
PaganiS., CrucianiL., ChianelliM., ProcacciniE., PozzilliP.. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients.Diabetes Res1989; 12: 199–201.
83.
ZarubaK., RastorferM., GrobP.J., Joller-JemelkaH., BollaK.. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination.Lancet1983; 26: 1245 (letter).
84.
DonatiD., GastaldiL.. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination.Nephron1988; 50: 133–6.
85.
MeuerS.C., DumannH., Meyer zum BuschenfeldeK.H.G., KohlerH.. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination.Lancet1989; i: 15–8.
86.
JungersP., DevillierP., SalomonH., CerisierJ.E., CouroucéA.M.. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine.Lancet1994; 344: 856–7.
87.
MauriM.J., VallesM., and The Collaborative Group of Girona. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients.Nephrol Dial Transplant1997; 12: 729–32.
88.
HessG., KreiterF., KostersW., DeuschK.. The effect of granulocyte-macrophage colony-stimulating factor (GM-GSF) on hepatitis B vaccination in haemodialysis patients.J Viral Hepatitis1996; 3: 149–53.
89.
SeaworthB., DruckerJ., StarlingJ., DruckerR., StevensC., HamiltonJ.. Hepatitis B vaccines in patients with chronic renal failure before dialysis.J Infect Dis1988; 157: 332–7.
90.
DukesC.S., StreetA.C., StarlingJ.F., HamiltonJ.D.. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis.Vaccine1993; 11: 1229–32.
91.
FabriziF., AndrulliS., BacchiniG., CortiM., LocatelliF.. Intradermal versus intramuscular hepatitis B vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation.Nephrol Dial Transplant1997; 12: 1204–11.
92.
MilichD.R., ThorntonG.B., NeurathA.R., KentS.B., MichelM.L., TiollaisP.. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.Science1985; 228: 1195–9.
93.
Smit-LeijsM.B., KramerP., HeijtinkR.A., HopW.C., SchalmS.W.. Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma-derived vaccine with and without pre-S2 antigen.Eur J Clin Invest1990; 20: 540–5.
94.
HaubitzM., EhlerdingG., BeigelA., HeuerU., HemmerlingA.E., ThomaH.A.. Clinical experience with a new recombinant hepatitis B-vaccine in previous non-responders with chronic renal insufficiency.Clin Nephrol1996; 45: 180–2.
95.
PerilloR.P., SchiffE.R., DavisG.L.. A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B.N Engl J Med1990; 323: 295–301.
96.
DuarteR., HuraibS., SaidR.. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis.Am J Kidney Dis1995; 25: 40–5.
97.
DienstagJ.L., PerrilloR.P., SchiffE.R., BartholomeuM., VicaryL., RubinM.A.. A preliminary trial of lamivudine for chronic hepatitis B infection.N Engl J Med1995; 33: 1657–9.
98.
PetersM.G., SingerG., HowardT.. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient.Transplantation1999; 68: 1912–4.
ChooQ., KuoG., WeinerA.J., OverbyL.R., BradleyD.W., HoughtonM.. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science1989; 244: 358–62.
103.
KuoG., ChooQ.L., AlterH.J.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.Science1989; 244: 362–4.
104.
HoughtonM., WeinerA., HanJ., KuoG., ChooQ.L.. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.Hepatology1991; 14: 381–8.
105.
SimmondsS., HolmesE.C., ChaT.A.. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 region.J Gen Virol1993; 74: 2391–9.
106.
EstebanJ.I., GonzalesA., HernandezJ.M.. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.N Engl J Med1990; 323: 1107–12.
107.
AlterH.J.. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus.Hepatology1992, 15: 350–3.
108.
BarreraJ.M., FrancisB., ErcillaG.. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.Vox Sang1995; 68: 15–8.
109.
van der PoelC.L., CuypersH.T., ReesinkH.W.. Confirmation of hepatitis C virus infection by new four antigen recombinant immunoblot assay.Lancet1991; 337: 317–9.
110.
WeinerA.J., KuoG., BradleyD.W.. Detection of hepatitis C viral sequences in non-A, non-B hepatitis.Lancet1990; 335: 1–3.
111.
SimmondsP., ZhangL.Q., WatsonH.G.. Hepatitis C quantification and sequencing in blood products, hemophiliacs, and drug users.Lancet1990; 336: 1469–71.
112.
BuschM.P., WilberJ.C., JhnsonP.J., ToblerL., EvansC.S.. Impact of specimen handling and storage on detection of hepatitis C virus RNA.Transfusion1992; 32: 420–5.
113.
AlterH.J., Sanchez-PescadorR., UrdeaM.S.. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA.J Viral Hepatitis1995; 2: 121–32.
114.
LauJ.Y.N., DavisG.L., KnifferJ.. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.Lancet1993; 341: 1501–4.
115.
GetzugT., LindsayK., BrezinaM., GitnickG.. Hepatitis C virus antibody in hemodialysis patients: prevalence and risk factors.Lancet1990; 335: 589 (letter).
116.
JeffersL.J., PerezO.G., de MedinaM.D.. Hepatitis C infection in two urban hemodialysis units.Kidney Int1990; 38: 320–2.
117.
SchlipkoterU., RoggendorfM., ErnstG.. Hepatitis C virus antibodies in hemodialysis patients.Lancet1990; 339: 1409 (letter).
118.
ZeldisJ.B., DepnerT.A., KuramotoI.K., GishR.G., HollandP.V.. The prevalence of hepatitis C virus antibodies among hemodialysis patients.Ann Intern Med1990; 112: 958–60.
119.
MullerG.Y., ZabaletaM.E., ArminioA.. Risk factors for dialysis-associated hepatitis C in Venezuela.Kidney Int1992; 41: 1055–8.
120.
HardyN.M., SandroniS., DanielsonS., WilsonD.J.. Antibody to hepatitis C virus increases with time on hemodialysis.Clin Nephrol1992; 38: 44–8.
121.
SheuJ.C., LeeS.H., WangJ.T., ShihL.N., WangT.H., ChenD.S.. Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan.J Med Virol1992; 37: 108–12.
122.
HayashiJ., NakashimaK., KaijamaW.. Prevalence of antibody to hepatitis C virus in hemodialysis patients.J Epidemiol1991; 134: 651–7.
123.
LinD.Y., LinH.H., HuangC.C., LiawY.F.. High incidence of hepatitis C virus infection in hemodialysis patients.Am J Kidney Dis1993; 21: 288–91.
124.
LinH.H., HuangC.C., SheenI.S., LinD.Y., LiawY.F.. Prevalence of antibodies to HCV in the hemodialysis unit.Am J Nephrol1991; 11: 192–4.
125.
MitwalliA., Al-MohayaS., Al WakeelE.J.. Hepatitis C virus infection in chronic renal failure patients.Am J Nephrol1992; 12: 288–91.
126.
MondelliM.U., SmedileV., PiazzaV.. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in hemodialysis patients.Nephrol Dial Transplant1991; 6: 480–3.
127.
FabriziF., RaffaeleL., BacchiniG.. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic hemodialysis patients: a study with second-generation assays.Nephrol Dial Transplant1993; 8: 744–7.
128.
MondelliM.U., CristinaG., PiazzaV., CerinoA., VillaG., SalvadeoA.. High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second generation assay.Nephron1992; 61: 351–2.
129.
BlackmoreT.K., MaddocksP., StawN.H., HatfieldP.. Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy and in the staff caring fro them.Aust NZ J Med1992; 22: 352–7.
130.
NiuM.T., ColemanP.J., AlterM.J.. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members.Am J Kidney Dis1993; 22: 568–73.
131.
FabriziF., LunghiG., RaffaeleL.. Serological survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs.Nephrol Dial Transplant1997; 12: 298–303.
132.
Cendoroglo-NetoM., DraibeS.A., SilvaA.E.. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission.Nephrol Dial Transplant1995; 10: 240–6.
133.
FabriziF., LunghiG., GuarnoriI.. Incidence of seroconversion for hepatitis C virus in chronic hemodialysis patients: a prospective study.Nephrol Dial Transplant1994; 9: 1611–5.
134.
NiuM.T., AlterM.J., KristensenC., MargolisH.S.. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus.Am J Kidney Dis1992; 4: 345–52.
135.
JadoulM., CornuC., van Ypersele deStrihou, and the Universitaires Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study.Kidney Int1998; 53: 1022–5.
136.
LombardiM., CerraiT., GeattiS.. Results of a national epidemiological investigation on HCV infection among dialysis patients.J Nephrol1999; 12: 322–7.
137.
DjordevicV., StojanovicK., StojanovicM., StefanovicV.. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study.Int J Artif Organs2000, 23: 181–8.
138.
HassanA.A., KhalilR.. Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusions, and liver disease.Saudi J Kidney Dis Transplant2000; 11: 72–5 (letter).
139.
CovicA., IancuL., ApetreiC.. Hepatitis virus infection in haemodialysis patients from Moldavia.Nephrol Dial Transplant1999; 14: 40–5.
140.
FabriziF., MartinP., DixitV.. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus.Am J Kidney Dis2000; 35: 122–9.
141.
FabriziF., MartinP., LunghiG., LocatelliF.. Membrane compatibility, flux and HCV infection in dialysis patients: newer evidence.Int J Artif Organs2000; 23: 296–304.
142.
FurusyoN., HayashiJ., AriyamaI.. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection.Am J Gastroenterol2000; 95: 491–6.
143.
PereiraB.J.G., LeveyA.S.. Hepatitis C virus infection and renal transplantation.Kidney Int1997; 51: 981–99.
144.
MartinP., CarterD., FabriziF.. Histopathological features of hepatitis C in renal transplant candidates.Transplantation2000; 69: 1479–84.
145.
Centers for Disease Control and Prevention.Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic liver disease.Morb Mortal Wkly Rep1998; 47(RR-19): 1–39.
146.
FernandezJ.L., RendoP., Del PinoN., ViolaL., the Nephrologists’ group for the Study of HCV infection. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels.J Viral Hepatitis1997; 4: 113–9.
147.
PattersonJ.L., Fernandez-LarssonR.. Molecular mechanisms of action of ribavirin.Rev Infect Dis1990; 12: 1139–46.
148.
FabriziF., MartinP.. Hepatitis E virus in end-stage renal disease.Int J Artif Organs1999; 22: 593–9.
149.
HalfonP., OuzanD., ChanasM.. High prevalence of hepatitis E virus antibody in hemodialysis patients.Lancet1994; 344: 746 (letter).
150.
CourtneyM.G., O'MahoneyM., AlbloushiS.. Hepatitis E virus antibody prevalence in hemodialysis patients.Lancet1994; 344: 1166 (letter).
151.
FabriziF., LunghiG., BacchiniG., CortiM., PaganoA., LocatelliF.. Hepatitis E virus infection in haemodialysis patients: a seroepidemiological survey.Nephrol Dial Transplant1997; 38: 133–6.
152.
MacedoG., ChavesA.P., PintoT.. Prevalence of hepatitis E virus antibody in haemodialysis patients.Lancet1994; 344: 1166 (letter).
153.
DalekosG.N., ZervouE., ElisafM.. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in a hemodialysis unit.Transfusion1998; 38: 589–95.
154.
ArinsoyT., YilmazM., DericiU., SindelS., TekinI., HasanogluE.. Prevalence of hepatitis E virus antibody in hemodialysis patients.Nephron1998; 80: 85 (letter).
155.
PsichigiouM., VaindirliE., TzalaE.. for the Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Hepatitis E virus (HEV) infection in haemodialysis patients.Nephrol Dial Transplant1996; 11: 1093–5.
156.
GessoniG., ManoniF.. Hepatitis E virus infection in northeast Italy: serological study in the open population and groups at risk.J Hepatitis1996; 11: 1093–5.
157.
SylvanS.P.E., JacobsonS.H., ChristensonB.. Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden.J Med Virol1998; 54: 38–43.
158.
ButiM., JardiR., CotrinaM.. Hepatitis E virus infection in acute hepatitis in Spain.J Virol Meth1995; 55: 48–54.
159.
FabriziF., MarcelliD., BacchiniG., GuarnoriI., ErbaG., LocatelliF.. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease.Nephrol Dial Transplant1994; 9: 780–4.
160.
FabriziF., LunghiG., PozziC.. GBV-C/HGV infection in end-stage renal disease: a serological and virological survey.J Nephrol2000; 13: 68–74.
161.
FornsX., Fernandez-LlamaP., CostaJ.. Hepatitis G virus infection in a hemodialysis unit: prevalence and clinical implications.Nephrol Dial Transplant1997; 12: 950–60.
162.
CornuC., JadoulM., LouteG., GoubauP.. Hepatitis G virus infection in haemodialysed patients: epidemiology and clinical relevance.Nephrol Dial Transplant1997; 12: 1326–9.
163.
SampietroM., BadalamentiS., GrazianiG.. Hepatitis G virus infection in hemodialysis patients.Kidney Int1997; 51: 348–52.
164.
FabriziF., LunghiG., BacchiniG.. Hepatitis G virus infection in chronic dialysis patients and kidney graft recipients.Nephrol Dial Transplant1997; 12: 1645–51.
165.
KallinowskiB., AhmadiR., SeippS., BommerJ., StremmelW.. Clinical impact of GB-C virus in haemodialysis patients.Nephrol Dial Transplant1998; 13: 93–8.
166.
TsudaF., HadiwondowoS., SawadaN.. Infection with GB virus C (GBV-C) in patients with chronic liver disease or on maintenance hemodialysis in Indonesia.J Med Virol1996; 49: 248–52.
167.
MartinP., FabriziF., DixitV.. Epidemiology and natural history of GBV-C/HGV infection in chronic hemodialysis patients.Am J Nephrol1999; 19: 535–40.
168.
ShengL., WidyastutiA., KosalaH.. High prevalence of hepatitis G virus infection compared with hepatitis C virus infection in patients undergoing chronic hemodialysis.Am J Kidney Dis1998; 31: 218–23.
169.
IdeuraT., TanakaE., NakatsujiY.. Clinical significance of hepatitis G virus infection in patients on long-term haemodialysis.J Gastroenterol Hepatol1997; 12: 762–5.
170.
De LamballerieX., CharrelR.N., DussolB.. Hepatitis GB virus C in patients on hemodialysis.N Engl J Med1996; 334: 1549.
171.
CampoN., SinelliN., BrizzolaraR.. Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients.Nephron1999; 82: 17–21.
172.
De MedinaM., AshbyM., SchluterV.. Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients.Am J Kidney Dis1998; 31: 224–8.
173.
ShibuyaA., TakeuchiA., KamataK., SaigenjiK., KobayashiN., YoshidaA.. Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population.Nephrol Dial Transplant1998; 13: 2033–6.
174.
DesassisJ.F., LapercheS., GiraultA.. Prevalence of present and past hepatitis G virus infection in a French haemodialysis centre.Nephrol Dial Transplant1999; 14: 2692–7.
175.
MasukoK., MitsuiT., IwanoK.. Infection with hepatitis GB virus C in patients on maintenance hemodialysis.N Engl J Med1996; 334: 1485–90.
176.
WatanabeT., IshiguroM., KametaniM.. GB virus C and hepatitis C virus infection in hemodialysis patients in eight Japanese centers.Nephron1997; 76: 171–5.
177.
NishizawaT., OkamotoH., KonishiK., YoshizawaH., MiyakawaY., MayumiM.. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology.Biochem Biophys Res Commun1997; 241: 92–7.
178.
SimmondsP., DavidsonF., LycettC.. Detection of a novel DNA virus (TTV) in blood donors and blood products.Lancet1998; 352: 191–5.
179.
CharltonM., AdjeiP., PoteruchaJ.. TT virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis.Hepatology1998; 28: 839–42.
180.
NakanoT., ParkY.M., MizokamiM.. TT virus infection among blood donors and patients with non-B, non-C liver diseases in Korea.J Hepatol1999; 30: 389–93.
181.
DavidsonF., MacDonaldD., MokiliJ.L.. Early acquisition of TT virus (TTV) in an area endemic for TTV infection.J Infect Dis1999; 179: 1070–6.
182.
OkamotoH., NishizawaT., KatoN.. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology.Hepatol Res1998; 10: 1–6.
183.
OkamotoH., AkahaneY., UkitaM.. Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis.J Med Virol1998; 56: 128–32.
184.
GallienP., BerlandY., OlmerM.. TT virus infection in French hemodialysis patients: study of prevalence and risk factors.J Clin Microbiol1999; 37: 2538–42.
185.
YukiN., KatoM., MasuzawaM.. Clinical implications of coinfection with a novel DNA virus (TTV) in hepatitis C virus carriers on maintenance hemodialysis.J Med Virol1999; 59: 431–8.
186.
FornsX., HegerichP., DarnellA., EmersonS.U., PurcellR.H., BikhJ.. High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis.J Med Virol1999; 59: 313–7.
